Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP312356.RAFft0Fikzlx7Okl6KovXtRohNaeakRoQbGkgGip6t83E130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP312356.RAFft0Fikzlx7Okl6KovXtRohNaeakRoQbGkgGip6t83E130_assertion type Assertion NP312356.RAFft0Fikzlx7Okl6KovXtRohNaeakRoQbGkgGip6t83E130_head.
- NP312356.RAFft0Fikzlx7Okl6KovXtRohNaeakRoQbGkgGip6t83E130_assertion description "[As a tumor marker, serum miR-181a expressed a higher level of sensitivity [55.28% (68/123)] in the early stage of BC diagnosis (ductal carcinoma in situ, TNM I and II) than the CA153 and CEA markers (8.13 and 7.32%, respectively).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP312356.RAFft0Fikzlx7Okl6KovXtRohNaeakRoQbGkgGip6t83E130_provenance.
- NP312356.RAFft0Fikzlx7Okl6KovXtRohNaeakRoQbGkgGip6t83E130_assertion evidence source_evidence_literature NP312356.RAFft0Fikzlx7Okl6KovXtRohNaeakRoQbGkgGip6t83E130_provenance.
- NP312356.RAFft0Fikzlx7Okl6KovXtRohNaeakRoQbGkgGip6t83E130_assertion SIO_000772 22692639 NP312356.RAFft0Fikzlx7Okl6KovXtRohNaeakRoQbGkgGip6t83E130_provenance.
- NP312356.RAFft0Fikzlx7Okl6KovXtRohNaeakRoQbGkgGip6t83E130_assertion wasDerivedFrom befree-20150227 NP312356.RAFft0Fikzlx7Okl6KovXtRohNaeakRoQbGkgGip6t83E130_provenance.
- NP312356.RAFft0Fikzlx7Okl6KovXtRohNaeakRoQbGkgGip6t83E130_assertion wasGeneratedBy ECO_0000203 NP312356.RAFft0Fikzlx7Okl6KovXtRohNaeakRoQbGkgGip6t83E130_provenance.